Aclaris Therapeutics (ACRS) announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the CEO through the first quarter of 2026 as part of his planned retirement. Kolbeck joins the team from Spirovant Sciences, where he served as Chief Scientific Officer and directed the company’s strategy related to new indications, targets, and investments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics assumed with an Overweight at Piper Sandler
- Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
- Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
- Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
- Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating